In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6 lbs (20.8%) over 80 weeks, with more than half no longer meeting the BMI criteria for obesity

Participants with a baseline BMI of 35 or higher who took retatrutide 12 mg lost up to an average of 60.8 lbs (23.4%) of their body weight

Retatrutide reduced A1C by up to an average of 1.6%, with up to 40.0% reaching an A1C of <5.7%

INDIANAPOLIS, Sept. 29, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced detailed results from TRIUMPH-2, a Phase 3 trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with type 2 diabetes and obesity or overweight. At 80 weeks, all doses of retatrutide (4 mg, 9 mg, and 12 mg) delivered substantial weight loss and reductions in A1C.1 Results were presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, and simultaneously published in The Lancet.

 

Lilly plans to submit a Biologics License Application (BLA) in Q1 2027 to the U.S. Food and Drug Administration. Additional results from the obstructive sleep apnea trial within TRIUMPH-2 will be presented at a future medical meeting and published in a peer-reviewed journal.